Skip to content

News

OCRFA Funded Study Focuses on the Dissemination of Ovarian ...

OCRFA Funded Study Focuses on the Dissemination of Ovarian Cancer

(April 27, 2018) An OCRFA supported study, recently published in Oncogene, delved into the mechanics of how ovarian cancer spreads throughout the body. Researchers at Johns Hopkins, including OCRFA grantee and lead author Ie-Ming Shih, MD, PhD, investigated spleen tyrosine kinase (SYK), which is heavily involved in ovarian cancer tumor progression, in an effort to … Continued

OCRFA Funded Study Explores Implant that Detects Ovarian Ca...

OCRFA Funded Study Explores Implant that Detects Ovarian Cancer Biomarker

(April 24, 2018) Science Advances recently published a study that succeeded in detecting HE4, a biomarker for high-grade serous ovarian cancer (HGSC), by implanting an optical sensor near a disease site in mice. HE4, like CA-125, is approved by the U.S. Food and Drug Administration as a biomarker for HGSC. However, these biomarkers are more … Continued

Statement from OCRFA President & CEO Audra Moran on th...

Statement from OCRFA President & CEO Audra Moran on the Death of U.S. Representative Louise Slaughter

(March 16, 2018) On behalf of Ovarian Cancer Research Alliance I want to extend our deepest condolences on the passing of U.S. Representative Louise Slaughter. As the author of the landmark Genetic Information Nondiscrimination Act (GINA), signed into law in 2008 after a 14-year battle, Representative Slaughter proved to be a tireless advocate for patients … Continued

Discovery of New Gene Mutation That Increases Ovarian Cance...

Discovery of New Gene Mutation That Increases Ovarian Cancer Risk, Passed Down Through Paternal Lineage

(February 22, 2018) Researchers at Roswell Park Comprehensive Cancer Center, including Kunle Odunsi, MD, PhD, senior author of the study and current OCRFA Scientific Advisory Committee member, have discovered a mutation of an unidentified gene that increases both the risk of early onset ovarian cancer and prostate cancer. Using the Familial Ovarian Cancer Registry at … Continued

OCRFA Awards $5.3 Million in Scientific Research Grants for...

OCRFA Awards $5.3 Million in Scientific Research Grants for 2018

(January 25, 2018) OCRFA has just awarded more than $5.3 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $80 million. This year’s grants have been awarded to twenty top scientists at sixteen leading medical centers across the country. “Our 2018 grantees are truly some of … Continued

Deadline: Midnight – Donation Match Ending 12/31

Deadline: Midnight – Donation Match Ending 12/31

Make your 2017 tax-deductible gift NOW! We work every day to fund cures, foster community, further conversations and ultimately, advance the cause. We do this by supporting women fighting ovarian cancer and the friends and families who love them, by working with scientists to eradicate the disease and policymakers who make it possible, and by … Continued

Today’s Gift Could Be Tomorrow’s Cure

Today’s Gift Could Be Tomorrow’s Cure

(December 28, 2017) Progress is being made every day, and scientists are on the threshold of many more important discoveries – but we need your help to continue investing in cutting-edge research that will one day lead to a cure, and to keep fighting on Capitol Hill for policies that help women receive the highest … Continued

OCRFA Research Shows Novel Combination Therapy Effective in...

OCRFA Research Shows Novel Combination Therapy Effective in Ovarian Cancer

(December 20, 2017) Cell Reports published new research from the Wistar Institute, which looked at the potential benefits of a therapy that combines PARP inhibitors and BET inhibitors for ovarian cancer patients without BRCA mutations. The research was funded in part by an OCRFA grant to Rugang, Zhang, PhD. PARP inhibitors have already been approved … Continued

OCRFA’s Impact in 2017

OCRFA’s Impact in 2017

(December 14, 2017) For over two decades, you have made it possible for OCRFA to fund the most innovative and promising science, resulting in research breakthroughs that have advanced our understanding of ovarian cancer, how it starts and new treatment options, and you have enabled OCRFA to successfully advocate for federal research dollars and provide … Continued

OCRFA Funded Research Identifies Mechanism Underlying Ovari...

OCRFA Funded Research Identifies Mechanism Underlying Ovarian Cancer Development

(November 22, 2017) A recent paper published in the Journal of Clinical Investigation reports that a subset of ovarian cancers reduce the expression of a critical gene involved in recycling the cells’ proteins, known as ubiquitin B (UBB). Silencing the expression of a closely related gene, also in the ubiquitin family, that performs an identical … Continued

OCRFA Funded Study Discovers 3 Key Genes in Prevention and ...

OCRFA Funded Study Discovers 3 Key Genes in Prevention and Treatment of BRCA1 and BRCA2 Tumors

(October 19, 2017) BRCA1 and BRCA2 are among the most frequently mutated genes in ovarian cancer. Studies conducted in the past two decades have shown that BRCA1 and BRCA2 play an essential role in protecting DNA from lesions that can lead to tumor formation. However, the factors that cause DNA lesions in BRCA1- and BRCA2-deficient … Continued

OCRFA’s Response to Trump Administration’s Birth Cont...

OCRFA’s Response to Trump Administration’s Birth Control Coverage Rollback

(Oct. 11, 2017) Last week, the Trump Administration issued a regulation to immediately allow employers to deny insurance coverage for birth control on the basis of their own moral or religious objections, undermining the landmark benefit under the Affordable Care Act (ACA) that guarantees coverage for contraception without co-pays or cost-sharing. Audra Moran, President and … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.